Cns Pharmaceuticals Inc (CNSP) Stock Price, Quote & News

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 800-946-9185

Website: www.cnspharma.com

Address:

2100 West Loop South, Suite 900, Houston, United States

kl7777 Oct. 24 at 7:58 PM

$CNSP Not much posts here. Need more volume to move back to $10 or so. Keep adding shares and hold until $20.

0 · Reply

ClarityOfPurpose Oct. 21 at 12:17 PM

$CNSP What a share increase proposal! Nothing surprises me with the audaciousness of this company.🤣

0 · Reply

kl7777 Oct. 21 at 3:54 AM

$CNSP Need more volume than today's one to move to $20. Then, more people would be interested. Write replies @cns_pharma on X.

0 · Reply

molero Oct. 20 at 2:15 PM

Nobody? $CNSP

0 · Reply

Axiomxk86426 Oct. 19 at 9:09 PM

$CNSP

0 · Reply

AcrossMarkets Oct. 19 at 8:41 PM

$CNSP is heating up after Orphan Drug status for its neuro-oncology lead TPI-287. The NASDAQ small-cap in the healthcare/biotech space shows major upside potential — analysts target ~$20 vs current ~$9. Are we looking at a bullish opportunity here? Read the blog for full context: https://www.acrossmarkets.icu/2025/10/small-cap-biotech-cns-pharmaceuticals.html

1 · Reply

Unalloyed Oct. 19 at 8:23 PM

$CNSP Glioblastoma pipeline

0 · Reply

Unalloyed Oct. 19 at 8:20 PM

$CNSP https://www.sec.gov/Archives/edgar/data/1729427/000168316825007157/cns_424b5.htm

0 · Reply

Unalloyed Oct. 19 at 8:19 PM

$CNSP Voting on huge AS increase. https://www.sec.gov/Archives/edgar/data/1729427/000168316825007498/cns_pre14a.htm

0 · Reply

Unalloyed Oct. 19 at 8:15 PM

$CNSP

0 · Reply

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 15, 2025, 8:05 AM EDT - 2 months ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 9:15 AM EDT - 2 months ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 22, 2025, 8:45 AM EDT - 3 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 18, 2025, 8:00 AM EDT - 3 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 9, 2025, 9:32 AM EDT - 3 months ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jun 24, 2025, 9:15 AM EDT - 4 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 5, 2025, 8:05 AM EDT - 5 months ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

May 16, 2025, 8:05 AM EDT - 5 months ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 9:35 AM EDT - 5 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 7:00 AM EDT - 5 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

Apr 1, 2025, 8:05 AM EDT - 7 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Mar 25, 2025, 12:05 PM EDT - 7 months ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 8:00 AM EDT - 7 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Feb 26, 2025, 9:05 AM EST - 8 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 20, 2025, 9:00 AM EST - 8 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 19, 2025, 9:00 AM EST - 8 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 18, 2025, 9:00 AM EST - 8 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 10, 2025, 8:00 AM EST - 9 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Dec 5, 2024, 9:10 AM EST - 11 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Nov 25, 2024, 9:00 AM EST - 11 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 18, 2024, 8:55 AM EST - 1 year ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 15, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 9:15 AM EST - 1 year ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 1, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Oct 23, 2024, 2:50 PM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 10, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 8, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Sep 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 12, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 4, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Aug 27, 2024, 9:10 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 22, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 25, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 16, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 3, 2024, 11:10 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 22, 2024, 10:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 1, 2024, 5:00 PM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

GILD REVB ZLAB

Jan 29, 2024, 9:00 PM EST - 1 year ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Jan 18, 2024, 8:45 AM EST - 1 year ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Jan 17, 2024, 8:45 AM EST - 1 year ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Dec 18, 2023, 8:35 AM EST - 2 years ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

kl7777 Oct. 24 at 7:58 PM

$CNSP Not much posts here. Need more volume to move back to $10 or so. Keep adding shares and hold until $20.

0 · Reply

ClarityOfPurpose Oct. 21 at 12:17 PM

$CNSP What a share increase proposal! Nothing surprises me with the audaciousness of this company.🤣

0 · Reply

kl7777 Oct. 21 at 3:54 AM

$CNSP Need more volume than today's one to move to $20. Then, more people would be interested. Write replies @cns_pharma on X.

0 · Reply

molero Oct. 20 at 2:15 PM

Nobody? $CNSP

0 · Reply

Axiomxk86426 Oct. 19 at 9:09 PM

$CNSP

0 · Reply

AcrossMarkets Oct. 19 at 8:41 PM

1 · Reply

Unalloyed Oct. 19 at 8:23 PM

$CNSP Glioblastoma pipeline

0 · Reply

Unalloyed Oct. 19 at 8:20 PM

$CNSP https://www.sec.gov/Archives/edgar/data/1729427/000168316825007157/cns_424b5.htm

0 · Reply

Unalloyed Oct. 19 at 8:19 PM

$CNSP Voting on huge AS increase. https://www.sec.gov/Archives/edgar/data/1729427/000168316825007498/cns_pre14a.htm

0 · Reply

Unalloyed Oct. 19 at 8:15 PM

$CNSP

0 · Reply

Balespur Oct. 18 at 9:37 PM

$CNSP expect they are prepping some news after a bit of silence. Back in here for a swing.

0 · Reply

kl7777 Oct. 17 at 5:19 PM

$CNSP Trading about 10% as of now vs. 65 day avg. More need to buy even few shares at asks to move the price up. Finish strong today.

0 · Reply

NetworkNewsWire Oct. 17 at 4:04 PM

Virtual Brain Tumors Could Transform How Cancer is Treated $CNSP https://ibn.fm/RU4hw #biomedstocks #Tumors

0 · Reply

Herbgator Oct. 16 at 4:40 PM

$CNSP ‪I posted on X for CNSP: John, have you even checked to see if MABA-related guidance work on rare disease is being delayed or paused by appropriations-funded FDA teams during the shutdown? Have you asked your FDA project manager if guidelines so important to CNSP are excepted or paused? Please update!Tks‬

0 · Reply

kl7777 Oct. 16 at 4:09 PM

$CNSP Reaching $10 or so is possible if more people buy couple shares at high limit/market asks.

0 · Reply

Zig2Zag Oct. 16 at 3:32 PM

$CNSP bought a few shares to sit and wait on

0 · Reply

Rick2058 Oct. 15 at 5:33 PM

$CNSP This minuscule volume micro-float could shape up to be a powder-keg.

0 · Reply

ahTony Oct. 14 at 11:32 PM

$CNSP what do we have here

0 · Reply

The_TendieMan_Cometh Oct. 14 at 2:37 PM

$CNSP silent but deadly? 🤔

0 · Reply

kl7777 Oct. 14 at 2:18 PM

$CNSP Buy few shares at high limit/market asks to move the price back to $10.

0 · Reply

The_TendieMan_Cometh Oct. 13 at 10:19 PM

$MSPR @tcwine I’m in this and $SLRX , $CLIK , and $CNSP - I like SLRX the best right now

0 · Reply

The_TendieMan_Cometh Oct. 13 at 10:10 PM

$CNSP when moon?

0 · Reply

Market Cap	4.63M
Revenue (ttm)	0.00
Net Income (ttm)	-14.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,100
Avg Vol	55,974
Day's Range	N/A - N/A
Shares Out	575,000.00
Stochastic %K	13%
Beta	2.68
Analysts	Strong Sell
Price Target	$20.00